The invention relates to the use of a G250 antibody for the manufacture of a pharmaceutical formulation for the treatment of renal cell carcinoma patients after surgery, and the use of a G250 antibody for the manufacture of an agent for eliciting a delayed immune response in a renal cell carcinoma patient.